AHCCCS · The Medical Pathway
AHCCCS and GLP-1 Medications: A Covered Pathway Through Liver Health
AHCCCS doesn't cover GLP-1s for weight loss alone. But Wegovy is FDA-approved to treat MASH, a liver condition that is common in people with obesity, and AHCCCS covers medically necessary treatment. A simple blood test tells us whether this pathway applies to you.
How Coverage Works
Why AHCCCS Covers GLP-1s for Some Members
Coverage here is based on a medical diagnosis, not on weight loss. Each case must be genuinely clinically indicated, which is why everything starts with screening, not with a prescription.
A real, common condition
MASH is a progressive liver disease that is common in people living with obesity and metabolic conditions, and it usually has no symptoms until it is advanced.
An FDA-approved treatment
In 2025, the FDA approved Wegovy for noncirrhotic MASH with moderate to advanced liver fibrosis, taken alongside diet and physical activity. That approval is the basis for AHCCCS coverage.
A simple first step
Screening starts with a FIB-4 score from a routine blood draw. No scans, no specialist referral, no cost surprises before you know whether the pathway applies.
Handled start to finish
If your results point to MASH-related fibrosis, we complete the workup, document the diagnosis correctly, and submit the prior authorization to AHCCCS for you.
Step One
The FIB-4 Blood Test
The FIB-4 is a score calculated from a routine blood draw, using your age, two liver enzymes, and your platelet count. It flags possible moderate to advanced liver scarring (fibrosis).
If your FIB-4 is elevated, we complete the evaluation for MASH-related fibrosis. When the diagnosis is confirmed, we document it correctly and pursue the covered, medically necessary treatment pathway with AHCCCS.
If your FIB-4 is normal, this pathway isn't appropriate for you, and we will say so plainly. Most patients in that situation look at our cash program at about $200-$225 a month.
If You Qualify
What Treatment Looks Like
The FDA approval requires Wegovy for MASH to be taken alongside diet and physical activity support. That support is built into our program, and with AHCCCS coverage there is no program fee. The Loli app even has a free version you can start with today.
Covered Wegovy treatment for your liver condition, prescribed alongside diet and activity support as the FDA label requires
Individual appointments with Zoë, our registered dietitian
Access to Terri, our health coach
The full Loli app with photo food logging, tracking, and education
No program fee: when AHCCCS covers your medication, the program is included
Common Questions
AHCCCS GLP-1 Coverage FAQs
Does AHCCCS cover Wegovy or Ozempic for weight loss?
What is MASH, or fatty liver disease?
What is a FIB-4 test?
How do I find out if I qualify?
What if I don't qualify through my liver health?
Is there a program fee with AHCCCS?
Get Started
Ask About FIB-4 Screening
Book a telehealth visit from anywhere in Arizona, or come see us in Tucson. One blood test starts the answer.
New patient
What type of consultation are you looking for?
Weight loss consult
Deidre Schodroski, FNP
New non-surgical patients must be Arizona residents. Prefer to talk it through first? Call (520) 298-3300.
Covered Differently?
Find the Pathway That Matches Your Coverage
This page is for informational purposes only and is not medical advice. Treatment is subject to a medical evaluation and individual eligibility. Pricing shown is approximate; unless noted, visit copays are additional and coverage details depend on your specific plan. Coverage through AHCCCS requires a genuine clinical diagnosis and prior authorization; screening results determine whether this pathway applies to you.